Cytoplasmic delivery and nuclear targeting of synthetic macromolecules

Journal of Controlled Release

Volumn 87, Issue 1-3, 2003, Pages 89-105

  Jensen, Keith D ^a   Nori, Aparna ^a   Tijerina, Monica ^a   Kopečková, Pavla ^a,b   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Antisense oligonucleotides; Cytoplasmic delivery; Drug delivery; N (2 Hydroxypropyl)methacrylamide; Subcellular trafficking

Indexed keywords

N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; OLIGONUCLEOTIDE; PHOTOSENSITIZING AGENT; TRANSACTIVATOR PROTEIN;

CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CONFERENCE PAPER; CONJUGATE; CORRELATION ANALYSIS; CYTOPLASM; DRUG DELIVERY SYSTEM; ENDOSOME; FLUORESCENCE; INCUBATION TIME; INTRACELLULAR TRANSPORT; LYSOSOME; MEMBRANE BINDING; MONITORING; PRIORITY JOURNAL; TIME; TOXICITY;

EID: 0037458919     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00352-8     Document Type: Conference Paper

References (83)

1. Lebedeva I., Benimetskaya L., Stein C.A., Vilenchik M. Cellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 50:(1):2000;101-119.
2. Crooke S.T. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta. 1489:(1):1999;31-44.
3. Kost J., Langer R. Responsive polymeric delivery systems. Adv. Drug Del. Rev. 46:(1-3):2001;125-148.
4. Langer R. Drug delivery and targeting. Nature. 392:(6679 Suppl.):1998;5-10.
5. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
6. Kopeček J., Kopečková P., Minko T., Lu Z.R. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:(1):2000;61-81.
7. Foster S., Lloyd J.B. Solute transport across the mammalian lysosome membrane. Biochim. Biophys. Acta. 947:(3):1988;465-491.
8. Ryser H.J.-P., Shen W.-C. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc. Natl. Acad. Sci. 75:(4):1978;3867-3870.
9. Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53:(18):1993;4238-4242.
10. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Lysosomotropic agents. Biochem. Pharmacol. 23:(18):1974;2495-2531.
11. Kopeček J. Biodegradation of polymers for biomedical use. Benoit H., Rempp P. IUPAC Macromolecules. 1982;305-320 Pergamon Press, Oxford.
12. Kopeček J. Controlled biodegradability of polymers - a key to drug delivery systems. Biomaterials. 5:(1):1984;19-25.
13. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs, US Pat. 5037883, August 6, 1991.
14. Kopečková P., Rathi R.C., Takada S., Říhová B., Berenson M.M., Kopeček J. Bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers for colon-specific drug delivery. J. Controlled Release. 28:1994;211-222.
15. Yeh P.Y., Berenson M.M., Samowitz W.S., Kopečková P., Kopeček J. Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J. Controlled Release. 36:1995;109-124.
16. Wang L., Kristensen J., Ruffner D.E. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of a thiol polymer and its conjugation to water-soluble molecules. Bioconjug. Chem. 9:(6):1998;749-757.
17. K.D. Jensen, P. Kopečková, J.H.B. Bridge, J. Kopeček, The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells, AAPS PharmSci [serial online] 3(4) (2001) Article 32.
18. Říhová B., Šrogl J., Jelínková M., Hovorka O., Burešová M., Šubr V., Ulbrich K. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility. Ann. NY Acad. Sci. 831:1997;57-71.
19. Šubr V., Duncan R., Kopeček J. Release of macromolecules and daunomycin from hydrophilic gels containing enzymatically degradable bonds. J. Biomater. Sci. Polym. Ed. 1:(4):1990;261-278.
20. Wang C., Stewart R.J., Kopeček J. Hybrid hydrogels assembled from synthetic polymers and coiled-coil protein domains. Nature. 397:(6718):1999;417-420.
21. Tang A., Wang C., Stewart R., Kopeček J. Self-assembled peptides exposing epitopes recognizable by human lymphoma cells. Bioconjug. Chem. 11:(3):2000;363-371.
22. Tang A., Kopeček J. Presentation of epitopes on genetically engineered peptides and selection of lymphoma-targeting moieties based on epitope biorecognition. Biomacromolecules. 3:(3):2002;421-431.
23. Duncan R., Cable H.C., Rejmanová P., Kopeček J., Lloyd J.B. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys. Acta. 799:(1):1984;1-8.
24. McCormick L.A., Seymour L.C.W., Duncan R., Kopeček J. Interaction of a cationic N-(2-hydroxypropyl)methacrylamide copolymer with rat visceral yolk sac cultured in vitro and rat liver in vivo. J. Bioact. Comp. Polym. 1:1986;4-19.
25. Drobník J., Kopeček J., Labský J., Rejmanová P., Exner J., Saudek V., Kálal J. Enzymatic cleavage of side-chains of synthetic water-soluble polymers. Makromol. Chem. 177:1976;2833-2848.
26. Šubr V., Strohalm J., Ulbrich K., Duncan R., Hume I.C. Polymers containing enzymatically degradable bonds. XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo. J. Controlled Release. 18:1992;123-132.
27. Choi W.-M., Kopečková P., Minko T., Kopeček J. Synthesis of HPMA copolymer containing adrimaycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells. J. Bioactive Compat. Polym. 14:1999;447-556.
28. Rejmanová P., Pohl J., Baudyš M., Kostka V., Kopeček J. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:1983;2009-2020.
29. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials. 6:(1):1985;45-48.
30. Duncan R., Cable H.C., Lloyd J.B., Rejmanová P., Kopeček J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Rep. 2:(12):1982;1041-1046.
31. Duncan R., Cable H.C., Lloyd J.B., Rejmanová P., Kopeček J. Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184:1983;1997-2008.
32. Říhová B., Ulbrich K., Kopeček J., Mančal P. Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers - potential hapten or drug carriers. Folia Microbiol. 28:(3):1983;217-227.
33. Říhová B., Kopeček J., Ulbrich K., Pospíšil M., Mančal P. Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials. 5:(3):1984;143-148.
34. Říhová R., Kopeček J., Ulbrich K., Chytrý V. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol. Chem. Suppl. 9:1985;13-24.
35. Šimečková J., Plocová D., Říhová B., Kopeček J. Activity of complement in the presence of N-(2-hydroxypropyl)methacrylamide copolymers. J. Bioact. Comp. Polym. 1:1986;20-31.
36. Říhová B., Kopeček J. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J. Controlled Release. 2:1985;289-310.
37. Flanagan P.A., Duncan R., Říhová B., Šubr V., Kopeček J. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates measured in A/J and B10 mice. J. Bioact. Comp. Polym. 5:1990;151-166.
38. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5:(1):1999;83-94.
39. Cartlidge S.A., Duncan R., Lloyd J.B., Kopečková-Rejmanová P., Kopeček J. Soluble crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 2. Effect of molecular weight on blood clearance and body distribution in the rat after intravenous administration. Distribution of unfractionated copolymer after intraperitoneal, subcutaneous or oral administration. J. Controlled Release. 4:1987;253-264.
40. Šprincl L., Exner J., Štěrba O., Kopeček J. New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl)methacrylamide] in a test organism. J. Biomed. Mater. Res. 10:(6):1976;953-963.
41. w) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res. 21:(11):1987;1341-1358.
42. Dvořák M., Kopečková P., Kopeček J. High-molecular weight HPMA copolymer-adriamycin conjugates. J. Controlled Release. 60:(2-3):1999;321-332.
43. Minko T., Kopečková P., Pozharov V., Jensen K.D., Kopeček J. The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors. Pharm. Res. 17:(5):2000;505-514.
44. Ashwell G., Morell A.G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. Relat. Areas Mol. Biol. 41:1974;99-128.
45. Schwartz A.L. The hepatic asialoglycoprotein receptor. CRC Crit. Rev. Biochem. 16:(3):1984;207-233.
46. Duncan R., Kopeček J., Rejmanová P., Lloyd J.B. Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta. 755:(3):1983;518-521.
47. Duncan R., Seymour L.C., Scarlett L., Lloyd J.B., Rejmanová P., Kopeček J. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta. 880:(1):1986;62-71.
48. Duncan R., Lloyd J.B., Rejmanová P., Kopeček J. Methods of targeting N-(2-hydroxypropyl)methacrylamide copolymers to particular cell types. Makromol. Chem. Suppl. 9:1985;3-12.
49. Cartlidge S.A., Duncan R., Lloyd J.B., Kopečková-Rejmanová P., Kopeček J. Soluble crosslinked N-2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 3. Targeting by incorporation of galactosamine residues. Effect of route of administration. J. Controlled Release. 4:1987;265-278.
50. Duncan R., Hume I.C., Kopečková P., Ulbrich K., Strohalm J., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Controlled Release. 10:1989;51-63.
51. Wedge S.R., Duncan R., Kopečková P. Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat. Br. J. Cancer. 63:(4):1991;546-549.
52. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin C.M., Doran J., David M., Anderson D., Christodoulou C., Young A.M., Hesslewood S., Kerr D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Controlled Release. 57:(3):1999;281-290.
53. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20:(6):2002;1668-1676.
54. Duncan R., Rejmanová P., Kopeček J., Lloyd J.B. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim. Biophys. Acta. 678:(1):1981;143-150.
55. Omelyanenko V., Kopečková P., Gentry C., Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Controlled Release. 53:(1-3):1998;25-37.
56. Omelyanenko V., Gentry C., Kopečková P., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer. 75:(4):1998;600-608.
57. Nori A., Jensen K.D., Kopečková P., Kopeček J. Cytoplasmic delivery and nuclear targeting of HPMA copolymer-tat conjugates to human ovarian carcinoma cells. 28th International Symposium on Controlled Release of Bioactive Materials (San Diego, CA) :2001;854-855.
58. de Smet M.D., Meenken C.J., van den Horn G.J. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7:(3-4):1999;189-198.
59. Tamm I., Dorken B., Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet. 358:(9280):2001;489-497.
60. Marcusson E.G., Bhat B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:(8):1998;2016-2023.
61. Merdan T., Kunath K., Fischer D., Kopeček J., Kissel T. Intracellular processing of poly(ethyleneimine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments. Pharm. Res. 19:(2):2002;140-146.
62. Jensen K.D., Kopečková P., Kopeček J. Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug. Chem. 13:(5):2002;975-984.
63. Crooke S.T. Basic principles of antisense therapeutics. Crooke S.T. Antisense Research and Application. 1998;1-50 Springer, Berlin.
64. Graham M.J., Crooke S.T., Monteith D.K., Cooper S.R., Lemonidis K.M., Stecker K.K., Martin M.J., Crooke R.M. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286:(1):1998;447-458.
65. Graham M.J., Crooke S.T., Lemonidis K.M., Gaus H.J., Templin M.V., Crooke R.M. Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem. Pharmacol. 62:(3):2001;297-306.
66. Chin D.J., Green G.A., Zon G., Szoka F.C. Jr., Straubinger R.M. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol. 2:(12):1990;1091-1100.
67. Lorenz P., Baker B.F., Bennett C.F., Spector D.L. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol. Biol. Cell. 9:(5):1998;1007-1023.
68. Fisher T.L., Terhorst T., Cao X., Wagner R.W. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 21:(16):1993;3857-3865.
69. Wagner R.W., Matteucci M.D., Lewis J.G., Gutierrez A.J., Moulds C., Froehler B.C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 260:(5113):1993;1510-1513.
70. 6 conjugates with chemotherapeutic activity in human ovarian carcinoma cells, (2002) submitted.
71. 6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials. 21:(21):2000;2203-2210.
72. 6 conjugates in a human ovarian carcinoma. J. Controlled Release. 74:(1-3):2001;269-273.
73. Hodel M.R., Corbett A.H., Hodel A.E. Dissection of a nuclear localization signal. J. Biol. Chem. 276:(2):2001;1317-1325.
74. Duncan R., Lloyd J.B. Pinocytosis in the rat visceral yolk sac. Effects of temperature, metabolic inhibitors and some other modifiers. Biochim. Biophys. Acta. 544:(3):1978;647-655.
75. Salzman N.H., Maxfield F.R. Fusion accessibility of endocytic compartments along the recycling and lysosomal endocytic pathways in intact cells. J. Cell. Biol. 109:(5):1989;2097-2104.
76. Lindgren M., Hallbrink M., Prochiantz A., Langel U. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:(3):2000;99-103.
77. Schwarze S.R., Hruska K.A., Dowdy S.F. Protein transduction: unrestricted delivery into all cells? Trends Cell. Biol. 10:(7):2000;290-295.
78. Nagahara H., Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N.A., Becker-Hapak M., Ezhevsky S.A., Dowdy S.F. Transduction of full-length Tat fusion proteins into mammalian cells: Tat-p27kip1 induces cell migration. Nat. Med. 4:(12):1998;1449-1452.
79. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 285:(5433):1999;1569-1572.
80. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18:(4):2000;410-414.
81. Torchilin V.P., Rammohan R., Weissig V., Levchenko T.S. Tat peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA. 98:(15):2001;8786-8791.
82. Schwarze S.R., Dowdy S.F. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21:(2):2000;45-48.
83. A. Nori, K.D. Jensen, M. Tijerina, P. Kopečková, J. Kopeček, Tat conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells, Bioconjug. Chem. (2003) in press.